Share on StockTwits

Allscripts Healthcare Solutions (NASDAQ:MDRX) Director Michael Klayko purchased 3,500 shares of the company’s stock in a transaction dated Monday, August 18th. The shares were purchased at an average cost of $14.41 per share, with a total value of $50,435.00. Following the completion of the purchase, the director now directly owns 46,257 shares in the company, valued at approximately $666,563. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Allscripts Healthcare Solutions (NASDAQ:MDRX) traded down 0.51% during mid-day trading on Thursday, hitting $14.605. The stock had a trading volume of 193,752 shares. Allscripts Healthcare Solutions has a 1-year low of $13.72 and a 1-year high of $19.68. The stock has a 50-day moving average of $15.72 and a 200-day moving average of $16.29. The company’s market cap is $2.631 billion.

Allscripts Healthcare Solutions (NASDAQ:MDRX) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.09 EPS for the quarter, meeting the Thomson Reuters consensus estimate of $0.09. The company had revenue of $351.30 million for the quarter, compared to the consensus estimate of $353.12 million. During the same quarter in the prior year, the company posted $0.13 earnings per share. The company’s quarterly revenue was up 1.9% on a year-over-year basis. Analysts expect that Allscripts Healthcare Solutions will post $0.38 EPS for the current fiscal year.

A number of research firms have recently commented on MDRX. Analysts at Credit Suisse reiterated an “outperform” rating on shares of Allscripts Healthcare Solutions in a research note on Tuesday. They now have a $18.00 price target on the stock, down previously from $19.00. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Allscripts Healthcare Solutions in a research note on Monday, August 11th. They now have a $16.00 price target on the stock. Finally, analysts at Raymond James reiterated an “outperform” rating on shares of Allscripts Healthcare Solutions in a research note on Friday, August 8th. They now have a $18.00 price target on the stock, down previously from $18.50. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $18.50.

Allscripts Healthcare Solutions, Inc (NASDAQ:MDRX) is a provider of clinical, financial, connectivity and information solutions and related professional services to hospitals, physicians and post-acute organizations.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.